Kwality has four EU-GMP units, plans expansion through FY29

Kwality says four of its five manufacturing units are approved under European Union Good Manufacturing Practice (EU-GMP), covering general products, beta lactams, oncology and cephalosporins, while its oncology expansion is due by June 2027 and its biologics, hormones and mega-general plans extend through financial year 2029 (FY29).

Which Kwality units are EU-GMP approved?

Kwality identifies Units 1, 2, 3 and 4 as EU-GMP approved, meaning four of its five listed operating units have that accreditation. Unit 1 produces general products, Unit 2 beta lactams, Unit 3 oncology products and Unit 4 cephalosporins. Unit 5, the biologics facility, is shown with a Pharmaceutical Inspection Co-operation Scheme (PICS) milestone in FY28 and an EU-GMP milestone by FY29 rather than current EU-GMP approval.

The regulatory table also lists PICS-related accreditations for Units 1 to 4, including Anvisa and Invima. Unit 1 additionally lists Sfda. Kwality says it completed more than 20 regulatory, customer and vendor audits during the past two years, and says its centralised corporate quality-assurance team applies audit learnings across manufacturing units.

Kwality also says it benchmarks plant practices against Form 483 observations across the industry. Its in-house research and development Innovation Centre at the Amritsar campus is approved by the Department of Scientific and Industrial Research (DSIR), according to the presentation.

What capacity does Kwality disclose by manufacturing unit?

Kwality's largest disclosed oral-solid capacity is at Unit 2, which has capacity for 3,000 million tablets and 1,500 million capsules. That exceeds Unit 1's 1,800 million tablets and 180 million capsules. Unit 1 has a broader product configuration, including ampoules, vials, oral liquids, suppositories, ointments and dental cartridges.

Unit 3 lists 47 million liquid injections for non-peptide products and 15 million lyophilised powder-and-cake products for peptide-based products. Unit 4 lists 19 million powder injections and 7 million dry-syrup units. These are different formats, but Unit 3's listed injectable categories are larger than Unit 4's disclosed powder-injection capacity.

Unit 5 adds biologics capacity, with a 100-litre bioreactor and an installation capacity of 500 litres, plus 1 million pre-filled syringes. Unit 1 also lists 1 million pre-filled syringes, alongside 100 million dry-powder injections and 3 million lyophilised products, showing the different configurations of the general and biologics units.

When are Kwality's new manufacturing facilities scheduled?

Kwality says the Unit 3 oncology capacity expansion is to be completed by June 2027. The presentation does not quantify the planned incremental output. Before the expansion, Unit 3's disclosed capacity includes 380 million tablets, 38 million capsules, 47 million liquid injections and 15 million lyophilised products.

Unit 6, which is intended for sex and synthetic hormones, has completed construction and has triggered a manufacturing audit, Kwality says. The company does not disclose output capacity for this plant. Its regulatory timetable lists PICS in FY28 and EU-GMP by FY29.

Unit 7 is described as a mega-general facility, for which land has been acquired, with completion targeted by FY29. Kwality does not provide the project cost, site area, construction start date, annual production capacity or regulatory-accreditation timetable for Unit 7.

How do Kwality's facilities relate to its current revenue mix?

Kwality reports that injectables accounted for 46% of revenue and tablets for 38%, together representing 84% of its disclosed dosage-form revenue mix. Capsules contributed 4%, ophthalmic products 4%, creams and ointments 3%, liquid externals and oral products 2%, and dry syrups, sachets and suppositories 1% each. Units 1 through 4 all have tablet or injectable capabilities.

The unit revenue mix changed between the first quarter of FY27 (Q1FY27) and the second quarter of FY27 (Q2FY27). Unit 1 declined from 63% to 61%, while Unit 3 increased from 20% to 22% and Unit 4 rose from 2% to 3%. Unit 2 fell from 15% to 14%, while Unit 5 remained at 1% in both quarters.

Kwality also reports overall capacity utilisation of about 35% in FY23, more than 65% in FY26 and more than 70% in the first half of FY27 (H1FY27). Cumulative filings rose from 75 in FY23 to more than 700 in FY26 and more than 750 in H1FY27. The presentation does not disclose utilisation or filing volumes by individual unit.

Conclusion

Kwality's current regulated manufacturing base comprises four EU-GMP-approved units across general products, beta lactams, oncology and cephalosporins. Its disclosed capacity is concentrated in oral solids and injectables, which correspond with revenue shares of 38% for tablets and 46% for injectables. Unit 3's revenue contribution also increased to 22% in Q2FY27 from 20% in Q1FY27.

The next disclosed milestones are completion of Unit 3's oncology expansion by June 2027, PICS milestones for Units 5 and 6 in FY28, and EU-GMP milestones for both facilities by FY29. Kwality also targets completion of the Unit 7 mega-general facility by FY29, although its capacity, cost and construction schedule beyond land acquisition remain undisclosed.